JP2019519503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019519503A5 JP2019519503A5 JP2018560135A JP2018560135A JP2019519503A5 JP 2019519503 A5 JP2019519503 A5 JP 2019519503A5 JP 2018560135 A JP2018560135 A JP 2018560135A JP 2018560135 A JP2018560135 A JP 2018560135A JP 2019519503 A5 JP2019519503 A5 JP 2019519503A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- substituted
- alkanediyl
- hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 claims description 174
- 229910052739 hydrogen Inorganic materials 0.000 claims description 159
- 239000001257 hydrogen Substances 0.000 claims description 159
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 152
- 150000002431 hydrogen Chemical class 0.000 claims description 126
- 150000001875 compounds Chemical class 0.000 claims description 101
- 125000004423 acyloxy group Chemical group 0.000 claims description 93
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 51
- 125000003342 alkenyl group Chemical group 0.000 claims description 49
- 125000005843 halogen group Chemical group 0.000 claims description 49
- 125000005017 substituted alkenyl group Chemical group 0.000 claims description 39
- 238000006467 substitution reaction Methods 0.000 claims description 36
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 33
- 239000000203 mixture Substances 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 16
- 108020004707 nucleic acids Proteins 0.000 claims description 9
- 150000007523 nucleic acids Chemical class 0.000 claims description 9
- 102000039446 nucleic acids Human genes 0.000 claims description 9
- 150000003431 steroids Chemical class 0.000 claims description 8
- 150000002632 lipids Chemical class 0.000 claims description 5
- 150000003904 phospholipids Chemical class 0.000 claims description 4
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims description 3
- -1 amino, hydroxy Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 125000001072 heteroaryl group Chemical group 0.000 claims description 3
- 239000003814 drug Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 125000000732 arylene group Chemical group 0.000 claims 6
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 6
- 150000001335 aliphatic alkanes Chemical class 0.000 description 39
- 238000000034 method Methods 0.000 description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 0 C**C(NC(C)C)=O Chemical compound C**C(NC(C)C)=O 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000003679 cervix uteri Anatomy 0.000 description 2
- 125000005415 substituted alkoxy group Chemical group 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 208000003837 Second Primary Neoplasms Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000000277 Splenic Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108091027544 Subgenomic mRNA Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 201000011061 large intestine cancer Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 201000002314 small intestine cancer Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 201000002471 spleen cancer Diseases 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022084888A JP7480220B2 (ja) | 2016-05-16 | 2022-05-25 | カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質 |
| JP2024070491A JP2024091896A (ja) | 2016-05-16 | 2024-04-24 | カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662337196P | 2016-05-16 | 2016-05-16 | |
| US62/337,196 | 2016-05-16 | ||
| PCT/US2017/032950 WO2017201076A1 (en) | 2016-05-16 | 2017-05-16 | Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022084888A Division JP7480220B2 (ja) | 2016-05-16 | 2022-05-25 | カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019519503A JP2019519503A (ja) | 2019-07-11 |
| JP2019519503A5 true JP2019519503A5 (enExample) | 2020-06-25 |
| JP7080826B2 JP7080826B2 (ja) | 2022-06-06 |
Family
ID=60326218
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018560135A Active JP7080826B2 (ja) | 2016-05-16 | 2017-05-16 | カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質 |
| JP2022084888A Active JP7480220B2 (ja) | 2016-05-16 | 2022-05-25 | カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質 |
| JP2024070491A Pending JP2024091896A (ja) | 2016-05-16 | 2024-04-24 | カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022084888A Active JP7480220B2 (ja) | 2016-05-16 | 2022-05-25 | カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質 |
| JP2024070491A Pending JP2024091896A (ja) | 2016-05-16 | 2024-04-24 | カチオン性スルホンアミドアミノ脂質および両親媒性両性イオンアミノ脂質 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US10562849B2 (enExample) |
| EP (1) | EP3458032A4 (enExample) |
| JP (3) | JP7080826B2 (enExample) |
| CN (2) | CN114656378A (enExample) |
| AU (4) | AU2017267634C1 (enExample) |
| CA (1) | CA3024129A1 (enExample) |
| WO (1) | WO2017201076A1 (enExample) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017267634C1 (en) * | 2016-05-16 | 2022-05-26 | The Board Of Regents Of The University Of Texas System | Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids |
| US20170354672A1 (en) * | 2016-05-16 | 2017-12-14 | The Board Of Regents Of The University Of Texas System | Compositions for the delivery of trna as nanoparticles and methods of use therewith |
| US11261113B2 (en) | 2017-08-30 | 2022-03-01 | Ecolab Usa Inc. | Molecules having one hydrophobic group and two identical hydrophilic ionic groups and compositions thereof and methods of preparation thereof |
| US11560575B2 (en) | 2017-12-29 | 2023-01-24 | Texas Tech University System | High efficient delivery of plasmid DNA into human and vertebrate primary cells in vitro and in vivo by nanocomplexes |
| CN112601718A (zh) | 2018-08-29 | 2021-04-02 | 埃科莱布美国股份有限公司 | 衍生自伯胺或多胺的多电荷阳离子化合物在水系统中控制微生物结垢的用途 |
| US11685709B2 (en) | 2018-08-29 | 2023-06-27 | Ecolab Usa Inc. | Multiple charged ionic compounds derived from polyamines and compositions thereof and use thereof as reverse emulsion breakers in oil and gas operations |
| US11236040B2 (en) * | 2018-08-29 | 2022-02-01 | Ecolab Usa Inc. | Multiple charged ionic compounds derived from polyamines and compositions thereof and methods of preparation thereof |
| US11084974B2 (en) | 2018-08-29 | 2021-08-10 | Championx Usa Inc. | Use of multiple charged cationic compounds derived from polyamines for clay stabilization in oil and gas operations |
| CA3110365C (en) | 2018-08-29 | 2023-05-09 | Ecolab Usa Inc. | Use of multiple charged ionic compounds derived from polyamines for waste water clarification |
| CN113365498B (zh) | 2019-01-29 | 2022-10-25 | 埃科莱布美国股份有限公司 | 阳离子糖基化合物用于在水系统中进行微生物结垢控制的用途 |
| CA3136427C (en) | 2019-04-16 | 2023-10-24 | Ecolab Usa Inc. | Use of multiple charged cationic compounds derived from polyamines and compositions thereof for corrosion inhibition in a water system |
| EP4013740B1 (en) * | 2019-08-12 | 2026-04-08 | Integrated Nanotherapeutics Inc. | Lipids for delivery of charged material, formulations thereof and method for making same |
| CA3182026A1 (en) | 2020-05-29 | 2021-12-02 | Flagship Pioneering Innovations Vi, Llc. | Trem compositions and methods relating thereto |
| IL298539A (en) | 2020-05-29 | 2023-01-01 | Flagship Pioneering Innovations Vi Llc | Trem compositions and methods relating thereto |
| AU2021327782A1 (en) * | 2020-08-21 | 2023-03-23 | The Board Of Regents Of The University Of Texas System | Functional ionizable phospholipids |
| KR20230092914A (ko) * | 2020-09-23 | 2023-06-26 | 트랜슬레이트 바이오 인코포레이티드 | Tes계 양이온성 지질 |
| BR112023012377A2 (pt) | 2020-12-23 | 2023-10-24 | Flagship Pioneering Innovations Vi Llc | Composições de trems modificadas e usos das mesmas |
| WO2022204219A1 (en) | 2021-03-22 | 2022-09-29 | Recode Therapeutics, Inc. | Compositions and methods for targeted delivery to cells |
| KR20230175196A (ko) | 2021-03-23 | 2023-12-29 | 리코드 테라퓨틱스, 인크. | 폴리뉴클레오티드 조성물, 관련된 제제, 및 이의 사용 방법 |
| US12104181B2 (en) | 2021-03-31 | 2024-10-01 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating viral infections targeting TRIM7 |
| EP4352240A4 (en) | 2021-06-09 | 2025-07-09 | Recode Therapeutics Inc | POLYNUCLEOTIDE COMPOSITIONS, RELATED FORMULATIONS AND METHODS OF USE THEREOF |
| EP4377457A1 (en) | 2021-07-26 | 2024-06-05 | Flagship Pioneering Innovations VI, LLC | Trem compositions and uses thereof |
| CN113461577B (zh) * | 2021-09-01 | 2021-12-14 | 中山大学附属第七医院(深圳) | 一种氨基脂质及其应用 |
| CN113816991B (zh) * | 2021-10-17 | 2023-12-15 | 拓新药业集团股份有限公司 | 一种氯化磷酸胆碱钙的制备方法 |
| US20250295687A1 (en) | 2022-05-09 | 2025-09-25 | Flagship Pioneering Innovations Vi, Llc | Trem compositions and methods of use for treating proliferative disorders |
| CN119522092A (zh) * | 2022-06-03 | 2025-02-25 | 比奥-特里普公司 | 用于核酸递送的基于多价分子的脂质纳米颗粒 |
| WO2023250112A1 (en) | 2022-06-22 | 2023-12-28 | Flagship Pioneering Innovations Vi, Llc | Compositions of modified trems and uses thereof |
| WO2024035952A1 (en) | 2022-08-12 | 2024-02-15 | Remix Therapeutics Inc. | Methods and compositions for modulating splicing at alternative splice sites |
| CN120359208A (zh) | 2022-12-23 | 2025-07-22 | 株式会社绿十字 | 可电离脂质及其用途 |
| JP2026514004A (ja) | 2023-04-12 | 2026-05-01 | フラッグシップ パイオニアリング イノベーションズ シックス，エルエルシー | 修飾されたｔｒｅｍ、組成物及びその関連方法 |
| EP4695391A1 (en) | 2023-04-12 | 2026-02-18 | Flagship Pioneering Innovations VI, LLC | Trems for use in correction of missense mutations |
| WO2024216243A2 (en) * | 2023-04-14 | 2024-10-17 | The Johns Hopkins University | Peptide-based vaccines and methods for treatment |
| WO2025059107A1 (en) * | 2023-09-11 | 2025-03-20 | The Trustees Of The University Of Pennsylvania | Degradable, branched lipid compounds, methods of preparation thereof, lipid nanoparticles (lnps) comprising the same, and methods of use thereof |
| WO2025080867A1 (en) * | 2023-10-10 | 2025-04-17 | The Board Of Regents Of The University Of Texas System | Ionizable lipids for improved mrna delivery |
| KR20250058661A (ko) * | 2023-10-19 | 2025-04-30 | 주식회사 삼양홀딩스 | 양이온성 지질 및 이의 제조방법 |
| AR134145A1 (es) | 2023-10-24 | 2025-12-03 | Green Cross Corp | Lípidos ionizables y sus usos |
| TW202525812A (zh) | 2023-10-24 | 2025-07-01 | 南韓商綠十字股份有限公司 | 可離子化脂質及其用途 |
| CN117482066B (zh) * | 2023-11-02 | 2024-08-13 | 深圳市易瑞生物技术股份有限公司 | 脂质组合物和用于脂质组合物的化合物 |
| WO2025097659A1 (en) * | 2023-11-08 | 2025-05-15 | Longuide Biopharma Corporation | Lipids and lipid nanoparticle formulations |
| CN118930449A (zh) * | 2024-07-18 | 2024-11-12 | 深圳厚存纳米药业有限公司 | 一种脂质化合物、脂质纳米粒及其制备方法和应用 |
Family Cites Families (126)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| JPS5927900A (ja) | 1982-08-09 | 1984-02-14 | Wakunaga Seiyaku Kk | 固定化オリゴヌクレオチド |
| FR2540122B1 (fr) | 1983-01-27 | 1985-11-29 | Centre Nat Rech Scient | Nouveaux composes comportant une sequence d'oligonucleotide liee a un agent d'intercalation, leur procede de synthese et leur application |
| US4605735A (en) | 1983-02-14 | 1986-08-12 | Wakunaga Seiyaku Kabushiki Kaisha | Oligonucleotide derivatives |
| US4948882A (en) | 1983-02-22 | 1990-08-14 | Syngene, Inc. | Single-stranded labelled oligonucleotides, reactive monomers and methods of synthesis |
| US4824941A (en) | 1983-03-10 | 1989-04-25 | Julian Gordon | Specific antibody to the native form of 2'5'-oligonucleotides, the method of preparation and the use as reagents in immunoassays or for binding 2'5'-oligonucleotides in biological systems |
| US4587044A (en) | 1983-09-01 | 1986-05-06 | The Johns Hopkins University | Linkage of proteins to nucleic acids |
| US5118802A (en) | 1983-12-20 | 1992-06-02 | California Institute Of Technology | DNA-reporter conjugates linked via the 2' or 5'-primary amino group of the 5'-terminal nucleoside |
| US5367066A (en) | 1984-10-16 | 1994-11-22 | Chiron Corporation | Oligonucleotides with selectably cleavable and/or abasic sites |
| US5430136A (en) | 1984-10-16 | 1995-07-04 | Chiron Corporation | Oligonucleotides having selectably cleavable and/or abasic sites |
| US5258506A (en) | 1984-10-16 | 1993-11-02 | Chiron Corporation | Photolabile reagents for incorporation into oligonucleotide chains |
| US4828979A (en) | 1984-11-08 | 1989-05-09 | Life Technologies, Inc. | Nucleotide analogs for nucleic acid labeling and detection |
| FR2575751B1 (fr) | 1985-01-08 | 1987-04-03 | Pasteur Institut | Nouveaux nucleosides de derives de l'adenosine, leur preparation et leurs applications biologiques |
| US4762779A (en) | 1985-06-13 | 1988-08-09 | Amgen Inc. | Compositions and methods for functionalizing nucleic acids |
| US5317098A (en) | 1986-03-17 | 1994-05-31 | Hiroaki Shizuya | Non-radioisotope tagging of fragments |
| JPS638396A (ja) | 1986-06-30 | 1988-01-14 | Wakunaga Pharmaceut Co Ltd | ポリ標識化オリゴヌクレオチド誘導体 |
| US4904582A (en) | 1987-06-11 | 1990-02-27 | Synthetic Genetics | Novel amphiphilic nucleic acid conjugates |
| DE3851889T2 (de) | 1987-06-24 | 1995-04-13 | Florey Howard Inst | Nukleosid-derivate. |
| US5585481A (en) | 1987-09-21 | 1996-12-17 | Gen-Probe Incorporated | Linking reagents for nucleotide probes |
| US5525465A (en) | 1987-10-28 | 1996-06-11 | Howard Florey Institute Of Experimental Physiology And Medicine | Oligonucleotide-polyamide conjugates and methods of production and applications of the same |
| DE3738460A1 (de) | 1987-11-12 | 1989-05-24 | Max Planck Gesellschaft | Modifizierte oligonukleotide |
| US5082830A (en) | 1988-02-26 | 1992-01-21 | Enzo Biochem, Inc. | End labeled nucleotide probe |
| US5109124A (en) | 1988-06-01 | 1992-04-28 | Biogen, Inc. | Nucleic acid probe linked to a label having a terminal cysteine |
| US5175273A (en) | 1988-07-01 | 1992-12-29 | Genentech, Inc. | Nucleic acid intercalating agents |
| US5262536A (en) | 1988-09-15 | 1993-11-16 | E. I. Du Pont De Nemours And Company | Reagents for the preparation of 5'-tagged oligonucleotides |
| US5512439A (en) | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
| US5457183A (en) | 1989-03-06 | 1995-10-10 | Board Of Regents, The University Of Texas System | Hydroxylated texaphyrins |
| US5599923A (en) | 1989-03-06 | 1997-02-04 | Board Of Regents, University Of Tx | Texaphyrin metal complexes having improved functionalization |
| US5391723A (en) | 1989-05-31 | 1995-02-21 | Neorx Corporation | Oligonucleotide conjugates |
| US4958013A (en) | 1989-06-06 | 1990-09-18 | Northwestern University | Cholesteryl modified oligonucleotides |
| US5451463A (en) | 1989-08-28 | 1995-09-19 | Clontech Laboratories, Inc. | Non-nucleoside 1,3-diol reagents for labeling synthetic oligonucleotides |
| US5134066A (en) | 1989-08-29 | 1992-07-28 | Monsanto Company | Improved probes using nucleosides containing 3-dezauracil analogs |
| US5254469A (en) | 1989-09-12 | 1993-10-19 | Eastman Kodak Company | Oligonucleotide-enzyme conjugate that can be used as a probe in hybridization assays and polymerase chain reaction procedures |
| US5292873A (en) | 1989-11-29 | 1994-03-08 | The Research Foundation Of State University Of New York | Nucleic acids labeled with naphthoquinone probe |
| US5130302A (en) | 1989-12-20 | 1992-07-14 | Boron Bilogicals, Inc. | Boronated nucleoside, nucleotide and oligonucleotide compounds, compositions and methods for using same |
| US5486603A (en) | 1990-01-08 | 1996-01-23 | Gilead Sciences, Inc. | Oligonucleotide having enhanced binding affinity |
| US5459255A (en) | 1990-01-11 | 1995-10-17 | Isis Pharmaceuticals, Inc. | N-2 substituted purines |
| US5681941A (en) | 1990-01-11 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Substituted purines and oligonucleotide cross-linking |
| US5587470A (en) | 1990-01-11 | 1996-12-24 | Isis Pharmaceuticals, Inc. | 3-deazapurines |
| US5578718A (en) | 1990-01-11 | 1996-11-26 | Isis Pharmaceuticals, Inc. | Thiol-derivatized nucleosides |
| AU7579991A (en) | 1990-02-20 | 1991-09-18 | Gilead Sciences, Inc. | Pseudonucleosides and pseudonucleotides and their polymers |
| US5214136A (en) | 1990-02-20 | 1993-05-25 | Gilead Sciences, Inc. | Anthraquinone-derivatives oligonucleotides |
| ATE167523T1 (de) | 1990-05-11 | 1998-07-15 | Microprobe Corp | Teststreifen zum eintauchen für nukleinsäure- hybridisierungsassays und verfahren zur kovalenten immobilisierung von oligonucleotiden |
| US5688941A (en) | 1990-07-27 | 1997-11-18 | Isis Pharmaceuticals, Inc. | Methods of making conjugated 4' desmethyl nucleoside analog compounds |
| US5138045A (en) | 1990-07-27 | 1992-08-11 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5608046A (en) | 1990-07-27 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Conjugated 4'-desmethyl nucleoside analog compounds |
| DE69126530T2 (de) | 1990-07-27 | 1998-02-05 | Isis Pharmaceutical, Inc., Carlsbad, Calif. | Nuklease resistente, pyrimidin modifizierte oligonukleotide, die die gen-expression detektieren und modulieren |
| US5218105A (en) | 1990-07-27 | 1993-06-08 | Isis Pharmaceuticals | Polyamine conjugated oligonucleotides |
| US5245022A (en) | 1990-08-03 | 1993-09-14 | Sterling Drug, Inc. | Exonuclease resistant terminally substituted oligonucleotides |
| US5512667A (en) | 1990-08-28 | 1996-04-30 | Reed; Michael W. | Trifunctional intermediates for preparing 3'-tailed oligonucleotides |
| US5432272A (en) | 1990-10-09 | 1995-07-11 | Benner; Steven A. | Method for incorporating into a DNA or RNA oligonucleotide using nucleotides bearing heterocyclic bases |
| EP0556301B1 (en) | 1990-11-08 | 2001-01-10 | Hybridon, Inc. | Incorporation of multiple reporter groups on synthetic oligonucleotides |
| US5371241A (en) | 1991-07-19 | 1994-12-06 | Pharmacia P-L Biochemicals Inc. | Fluorescein labelled phosphoramidites |
| US5594121A (en) | 1991-11-07 | 1997-01-14 | Gilead Sciences, Inc. | Enhanced triple-helix and double-helix formation with oligomers containing modified purines |
| EP1256589A3 (en) | 1991-11-26 | 2003-09-17 | Isis Pharmaceuticals, Inc. | Oligomers containing modified pyrimidines |
| US5484908A (en) | 1991-11-26 | 1996-01-16 | Gilead Sciences, Inc. | Oligonucleotides containing 5-propynyl pyrimidines |
| TW393513B (en) | 1991-11-26 | 2000-06-11 | Isis Pharmaceuticals Inc | Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines |
| US5595726A (en) | 1992-01-21 | 1997-01-21 | Pharmacyclics, Inc. | Chromophore probe for detection of nucleic acid |
| US5565552A (en) | 1992-01-21 | 1996-10-15 | Pharmacyclics, Inc. | Method of expanded porphyrin-oligonucleotide conjugate synthesis |
| US6806084B1 (en) | 1992-06-04 | 2004-10-19 | The Regents Of The University Of California | Methods for compositions for in vivo gene delivery |
| US5272250A (en) | 1992-07-10 | 1993-12-21 | Spielvogel Bernard F | Boronated phosphoramidate compounds |
| RU95114435A (ru) | 1992-12-14 | 1997-05-20 | Ханивелл Инк. (Us) | Система с бесщеточным двигателем постоянного тока |
| US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
| US5502177A (en) | 1993-09-17 | 1996-03-26 | Gilead Sciences, Inc. | Pyrimidine derivatives for labeled binding partners |
| US5457187A (en) | 1993-12-08 | 1995-10-10 | Board Of Regents University Of Nebraska | Oligonucleotides containing 5-fluorouracil |
| US5596091A (en) | 1994-03-18 | 1997-01-21 | The Regents Of The University Of California | Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides |
| US5525711A (en) | 1994-05-18 | 1996-06-11 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Pteridine nucleotide analogs as fluorescent DNA probes |
| US5597696A (en) | 1994-07-18 | 1997-01-28 | Becton Dickinson And Company | Covalent cyanine dye oligonucleotide conjugates |
| US5580731A (en) | 1994-08-25 | 1996-12-03 | Chiron Corporation | N-4 modified pyrimidine deoxynucleotides and oligonucleotide probes synthesized therewith |
| US5820873A (en) | 1994-09-30 | 1998-10-13 | The University Of British Columbia | Polyethylene glycol modified ceramide lipids and liposome uses thereof |
| US20050032068A1 (en) | 2002-11-05 | 2005-02-10 | Prakash Thazha P. | Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| US6770748B2 (en) | 1997-03-07 | 2004-08-03 | Takeshi Imanishi | Bicyclonucleoside and oligonucleotide analogue |
| JP3756313B2 (ja) | 1997-03-07 | 2006-03-15 | 武 今西 | 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体 |
| WO1998051278A2 (en) * | 1997-05-14 | 1998-11-19 | Inex Pharmaceuticals Corporation | High efficiency encapsulation of charged therapeutic agents in lipid vesicles |
| US6794499B2 (en) | 1997-09-12 | 2004-09-21 | Exiqon A/S | Oligonucleotide analogues |
| US6506559B1 (en) | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| BRPI9908967B1 (pt) | 1998-03-20 | 2017-05-30 | Benitec Australia Ltd | processos para reprimir, retardar ou de outro modo reduzir a expressão de um gene alvo em uma célula de planta |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| WO1999054459A2 (en) | 1998-04-20 | 1999-10-28 | Ribozyme Pharmaceuticals, Inc. | Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| US6656498B1 (en) * | 1998-11-25 | 2003-12-02 | Vanderbilt University | Cationic liposomes for gene transfer |
| NZ514348A (en) | 1999-05-04 | 2004-05-28 | Exiqon As | L-ribo-LNA analogues |
| US6525191B1 (en) | 1999-05-11 | 2003-02-25 | Kanda S. Ramasamy | Conformationally constrained L-nucleosides |
| WO2001006011A2 (en) | 1999-07-14 | 2001-01-25 | Genometrix Genomics, Inc. | Arrays comprising non-covalently associated nucleic acid probes and methods for making and using them |
| EP1235842A4 (en) | 1999-10-15 | 2003-04-23 | Univ Massachusetts | Rna interference pathway genes as tools for targeted genetic interference |
| CN1254234C (zh) * | 2000-06-09 | 2006-05-03 | 莱古伦公司 | 质粒dna(lipogenestm)和含细胞核定位信号/促融合肽缀合物的治疗剂包封到定向脂质体复合体中 |
| US20040019001A1 (en) | 2002-02-20 | 2004-01-29 | Mcswiggen James A. | RNA interference mediated inhibition of protein typrosine phosphatase-1B (PTP-1B) gene expression using short interfering RNA |
| WO2004041889A2 (en) | 2002-11-05 | 2004-05-21 | Isis Pharmaceuticals, Inc. | Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| WO2004043979A2 (en) | 2002-11-05 | 2004-05-27 | Isis Pharmaceuticals, Inc. | Sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation |
| WO2004106356A1 (en) | 2003-05-27 | 2004-12-09 | Syddansk Universitet | Functionalized nucleotide derivatives |
| EP1661905B9 (en) | 2003-08-28 | 2012-12-19 | IMANISHI, Takeshi | Novel artificial nucleic acids of n-o bond crosslinkage type |
| JP5379347B2 (ja) | 2003-09-18 | 2013-12-25 | アイシス ファーマシューティカルズ， インコーポレーテッド | ４’−チオヌクレオシドおよびオリゴマー化合物 |
| EP1547582A1 (en) * | 2003-12-23 | 2005-06-29 | MediGene Oncology GmbH | Method of producing lipid complexed camptothecin-carboxylate |
| WO2007086883A2 (en) * | 2005-02-14 | 2007-08-02 | Sirna Therapeutics, Inc. | Cationic lipids and formulated molecular compositions containing them |
| EP1962862B1 (en) * | 2005-12-19 | 2013-09-04 | Æterna Zentaris GmbH | Alkyl phospholipid derivatives with reduced cytotoxicity and uses therof |
| WO2007080902A1 (ja) | 2006-01-11 | 2007-07-19 | Kyowa Hakko Kogyo Co., Ltd. | 眼球において標的遺伝子の発現を抑制する組成物および眼球における疾患の治療剤 |
| ES2351674T3 (es) | 2006-01-27 | 2011-02-09 | Isis Pharmaceuticals, Inc. | Análogos de ácidos nucleicos bicíclicos modificados en la posición 6. |
| BRPI0710866A2 (pt) * | 2006-04-26 | 2012-08-14 | Hoffmann La Roche | compostos farmacÊuticos |
| CA2651453C (en) | 2006-05-11 | 2014-10-14 | Isis Pharmaceuticals, Inc. | 5'-modified bicyclic nucleic acid analogs |
| US7411002B2 (en) * | 2006-06-07 | 2008-08-12 | The University Of Kansas | Polycationic sulfonamides and use thereof |
| WO2008011561A2 (en) * | 2006-07-21 | 2008-01-24 | Massachusetts Institute Of Technology | End-modified poly(beta-amino esters) and uses thereof |
| WO2008101157A1 (en) | 2007-02-15 | 2008-08-21 | Isis Pharmaceuticals, Inc. | 5'-substituted-2'-f modified nucleosides and oligomeric compounds prepared therefrom |
| JP2010519203A (ja) * | 2007-02-16 | 2010-06-03 | メルク・シャープ・エンド・ドーム・コーポレイション | 生物活性分子の活性を強化するための組成物及び方法 |
| LT2494993T (lt) * | 2007-05-04 | 2018-12-27 | Marina Biotech, Inc. | Aminorūgščių lipidai ir jų panaudojimas |
| EP2170917B1 (en) | 2007-05-30 | 2012-06-27 | Isis Pharmaceuticals, Inc. | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs |
| EP2173760B2 (en) | 2007-06-08 | 2015-11-04 | Isis Pharmaceuticals, Inc. | Carbocyclic bicyclic nucleic acid analogs |
| EP2176280B2 (en) | 2007-07-05 | 2015-06-24 | Isis Pharmaceuticals, Inc. | 6-disubstituted bicyclic nucleic acid analogs |
| KR20090082155A (ko) * | 2008-01-24 | 2009-07-29 | 한국생명공학연구원 | 신규한 디아민 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 포함하는 암 치료용 약학 조성물 |
| EP3604533A1 (en) | 2008-04-11 | 2020-02-05 | Arbutus Biopharma Corporation | Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components |
| JP5777519B2 (ja) * | 2008-10-09 | 2015-09-09 | テクミラ ファーマシューティカルズ コーポレイション | 改良されたアミノ脂質および核酸の送達方法 |
| CA2742880A1 (en) | 2008-11-06 | 2010-05-14 | University Of Washington | Multiblock copolymers |
| MX2011004859A (es) | 2008-11-07 | 2011-08-03 | Massachusetts Inst Technology | Lipidoides de aminoalcohol y usos de los mismos. |
| WO2010071772A2 (en) * | 2008-12-15 | 2010-06-24 | The Penn State Research Foundation | Synthesis of 3b-amino-5-cholestene and related 3b-halides involving i-steroid and retro-i-steroid rearrangements |
| AU2010257181A1 (en) | 2009-06-02 | 2012-01-12 | Brian Charles Keller | Pure PEG-lipid conjugates |
| CN102020980B (zh) * | 2009-09-16 | 2013-05-01 | 中国海洋石油总公司 | 一种用于防止地层水锁的组合物及其应用 |
| WO2011056682A1 (en) | 2009-10-27 | 2011-05-12 | The University Of British Columbia | Reverse head group lipids, lipid particle compositions comprising reverse headgroup lipids, and methods for the delivery of nucleic acids |
| FR2958646B1 (fr) | 2010-04-07 | 2012-05-18 | Adocia | Polysaccharides comportant des groupes fonctionnels carboxyles substitues par un derive d'acide hydrophobe. |
| WO2012049307A2 (en) * | 2010-10-15 | 2012-04-19 | Novo Nordisk A/S | Novel n-terminally modified insulin derivatives |
| CN103153347A (zh) * | 2010-10-21 | 2013-06-12 | 默沙东公司 | 用于寡核苷酸递送的新型低分子量阳离子脂质 |
| TWI658830B (zh) | 2011-06-08 | 2019-05-11 | 日東電工股份有限公司 | Ｈｓｐ47表現調控強化用類視色素脂質體 |
| KR102029654B1 (ko) * | 2011-06-08 | 2019-10-08 | 닛토덴코 가부시키가이샤 | 표적 약물 전달체 및 ｓｉＲＮＡ 활성을 증가시키는 화합물 |
| WO2013032643A2 (en) * | 2011-08-31 | 2013-03-07 | Dicerna Pharmaceuticals, Inc. | Lipids capable of conformational change and their use in formulations to deliver therapeutic agents to cells |
| CN102698648A (zh) * | 2012-06-27 | 2012-10-03 | 东北石油大学 | 一种树枝状磺酸盐型四聚表面活性剂及其制备方法 |
| US20160128944A1 (en) | 2013-06-04 | 2016-05-12 | Vyome Biosciences Pvt. Ltd. | Coated particles and compositions comprising same |
| WO2015082656A1 (en) | 2013-12-04 | 2015-06-11 | Nexdot | Nanoparticles complexed with functionalizable enhanced affinity ligands and use thereof |
| SI3097076T1 (sl) | 2014-01-22 | 2019-10-30 | Max Delbrueck Centrum Fuer Molekulare Medizin | Novi derivati CYP-eikozanoida |
| AU2017267634C1 (en) * | 2016-05-16 | 2022-05-26 | The Board Of Regents Of The University Of Texas System | Cationic sulfonamide amino lipids and amphiphilic zwitterionic amino lipids |
-
2017
- 2017-05-16 AU AU2017267634A patent/AU2017267634C1/en active Active
- 2017-05-16 WO PCT/US2017/032950 patent/WO2017201076A1/en not_active Ceased
- 2017-05-16 EP EP17800030.3A patent/EP3458032A4/en active Pending
- 2017-05-16 CN CN202210228264.7A patent/CN114656378A/zh active Pending
- 2017-05-16 US US15/597,049 patent/US10562849B2/en active Active
- 2017-05-16 CN CN201780041000.8A patent/CN109414408B/zh active Active
- 2017-05-16 CA CA3024129A patent/CA3024129A1/en active Pending
- 2017-05-16 JP JP2018560135A patent/JP7080826B2/ja active Active
-
2020
- 2020-01-15 US US16/744,118 patent/US11542229B2/en active Active
-
2021
- 2021-08-11 US US17/399,774 patent/US11685710B2/en active Active
-
2022
- 2022-03-29 AU AU2022202140A patent/AU2022202140B2/en active Active
- 2022-05-25 JP JP2022084888A patent/JP7480220B2/ja active Active
-
2023
- 2023-05-10 US US18/315,446 patent/US12252464B2/en active Active
- 2023-11-06 AU AU2023263423A patent/AU2023263423B2/en active Active
-
2024
- 2024-04-24 JP JP2024070491A patent/JP2024091896A/ja active Pending
-
2025
- 2025-01-13 US US19/019,247 patent/US20250270169A1/en active Pending
-
2026
- 2026-04-07 AU AU2026202591A patent/AU2026202591A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016506916A5 (enExample) | ||
| JP2022116006A (ja) | ホスホロチオエート化オリゴデオキシヌクレオチドを含む化合物及び組成物、ならびにそれらの使用法 | |
| JP5860872B2 (ja) | ホスファプラチン、及び癌治療のためのそれらの使用 | |
| JP2008536807A5 (enExample) | ||
| JP2016531871A (ja) | 粘膜炎を治療および／または予防するための方法および組成物 | |
| TW201004658A (en) | Nanoparticle compositions for nucleic acids delivery system | |
| JP2019526560A5 (enExample) | ||
| CN104755455B (zh) | 可用于治疗癌症的巨大戟醇衍生化合物 | |
| JP2021169534A (ja) | 化学療法の改善 | |
| CA2585125A1 (en) | Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents | |
| TWI332007B (en) | Use of alkylphosphocholines in combination with antitumor medicaments for the treatment of benign and malignant oncoses in humans and animals | |
| JP4814245B2 (ja) | 低酸素選択性抗腫瘍剤としてのスルホニルヒドラジンのリン酸含有プロドラッグ | |
| CN107137407B (zh) | 一种vegfr抑制剂在制备治疗胰腺癌的药物中的用途 | |
| JP5934848B1 (ja) | 局所投与用リポプレックスの新規製造方法及び該リポプレックスを使用する抗腫瘍剤 | |
| CN100526324C (zh) | 制备反式-或顺式-二铵二氯二羟合铂(ⅳ)的方法及其用于制备药物有效物质的用途 | |
| US10111955B2 (en) | PEG derivative | |
| KR102317559B1 (ko) | 암을 치료하기 위한 신규 화합물, 이를 포함하는 약제학적 조성물 및 이의 제조방법 | |
| Ji et al. | Hypoxia‐Activated Imidazoquinoline Prodrug Nanoparticles Potentiate Radiofrequency Ablation‐Mediated Antitumor Immunity Against Hepatocellular Carcinoma | |
| JP2020530471A (ja) | ＭＥＫ／ＰＩ３Ｋ、ＪＡＫ／ＭＥＫ、ＪＡＫ／ＰＩ３Ｋ／ｍＴＯＲおよびＭＥＫ／ＰＩ３Ｋ／ｍＴＯＲの生物学的経路の阻害剤、および治療化合物のリンパ取り込み、生物学的利用能、および溶解性を改善する方法 | |
| CN112546024B (zh) | 一种超分子纳米药物及在制备抗肿瘤制剂中的应用 | |
| JP2018527372A5 (enExample) | ||
| CN105899486A (zh) | 用于治疗癌症的化合物和方法 | |
| WO2006062072A1 (ja) | 転移癌治療剤および癌転移抑制剤 | |
| CN1533273A (zh) | 紫杉烷类药物的节拍式给药 | |
| JP2011502985A5 (enExample) |